Unfortunately, selective METTL3/METTL14 inhibitors for cancer therapies are not yet available, but bisubstrate inhibitors are promising small-molecules in that they can be developed to be effective METTL3/METTL14 targeting agents (103, 105). Here, METTL3 is linked to cancer.